- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01459419
Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects
October 23, 2011 updated by: Inspira Medical AB
A Phase IIa Safety Study of Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects, a Single-blind, Randomized, Controlled Multi-center Study.
The use of oral aCD3 Monoclonal antibody (MAb) alone in subjects with hepatitis C is justified on the basis of scientific and medical reasons.
There are data in multiple animal models that aCD3-alone confers efficacy in models of inflammatory or autoimmune disease and induces regulatory T cells and immune-modulation as desired in clinical studies.
These observations are reinforced by data in the Phase 1 clinical study showing that aCD3-alone induced the desired immune-modulation in terms of immunological markers for regulatory T cells and appropriate rises and declines in certain cytokine levels.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Oral aCD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days.
Up of 9 subjects will be treated at each dosage level, and up to 9 subjects will receive placebo buffered in normal saline that is used as diluents for the MAb.
One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken orally as part of the study drug cocktail in order to neutralize stomach pH for enhancing stability of the MAb.
During the treatment period, subjects will ingest the study drug/s every day for 30 days, and will be followed for clinical and laboratory effects.
Subjects will be followed up to Day 60 (30 days after termination of treatment)
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Waldemar Halota, Prof.
- Phone Number: +48 52 325 56
- Email: kikchzak@cm.umk.pl
Study Locations
-
-
-
Wien, Austria, A-1090
- Univ.Klinik für Innere Medizin IV
-
Contact:
- Peter Ferenci, Prof.Dr.
- Phone Number: +43 1 40400 4741
- Email: peter.ferenci@meduniwien.ac.at
-
Principal Investigator:
- Peter Ferenci, Prof.Dr.
-
-
-
-
-
Bydgoszcz, Poland, 85 030
- Katedra i Klinika Chorób Zakaźnych i Hepatologii Wojewódzki Szpital Obserwacyjno - Zakaźny im. Tadeusza Browicza
-
Contact:
- Waldemar Halota, Prof
- Phone Number: >+48 52 325 5605
- Email: kikchzak@cm.umk.pl
-
Principal Investigator:
- Waldemar Halota, Prof
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
- Subjects who have completed the informed consent process culminating with written informed consent by the subject.
- Men and women age 18 to 65 years (inclusive).
- Diagnosis of chronic active HCV infection was based on liver biopsy (within 3 years of initiation of study),
- Patients who failed treatment with Interferon or Peg-Interferon and Ribavirin (<2-log change in HCV level during the 12 weeks of treatment)
- HCV RNA in blood for at Screening Visit, ≥600 copies/mL
- Abstinence from any alternative medications or vitamin-D-containing supplements for three months prior to initiation of therapy was stipulated.
- Compensated liver disease with the following maximum hematologic, biochemical and serologic criteria at the Screening visit (WNL=within normal limits) Hemoglobin ≥ 12 g/dl for women and ≥ 13 g/dl for men, WBC > 3000/mm3, Platelets > 100,000/mm3, Direct bilirubin - WNL. Indirect bilirubin - WNL, Albumin - WNL, Serum Creatinine - WNL. Child-Pugh score ≤ 6.
- Fasting glucose should be 70 -140 mg/dl, results between 116-140 require HbA1c < 7.5%
- Antinuclear antibodies (ANA) up to +1
- HCV Genotype I patients
Exclusion Criteria:
- Subjects who have undergone surgery within the last 3 months.
- Subjects who have had a prior gastrointestinal surgery.
- Subjects with organ transplants other than cornea or hair transplant.
- Subjects with Inflammatory Bowel Disease, malabsorption, and symptoms of diarrhea.
- Subjects with a clinically significant (during last 3 months) infectious, immune-mediated or malignant disease.
- Subjects who are receiving an elemental diet or parenteral nutrition.
- Subjects who have been treated with any type of immune modulatory drug including systemic steroids or NSAID within the last 4 weeks.
- Subjects who have received either methotrexate or cyclosporine or anti-TNF (infliximab, Remicade) or anti-integrin (namixilab) at any time or who have participated in any other clinical trial within the last 3 months.
- Subjects with a history of coagulopathy.
- ALT level more than 10 times the normal limit.
- Women with childbearing potential unless using adequate contraception (either IUD, oral or Depo-provera contraceptive, or barrier plus spermicide); pregnant or breastfeeding mothers.
- Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason.
- Subjects who are HIV-positive.
- Subjects who are positive for anti-HBcAg
- Subjects with active CMV infection.
- Subjects with autoimmune hepatitis
- Subjects with IgG anti-cardiolipin antibody >16 IU.
- Any prior exposure to anti-CD3 MAb.
- Known sensitivity to any ingredients in the study drug
- Any know autoimmune disease except for the studied disorders
- Subjects with excess alcohol use (> 30 g/day)
- Subjects with drug addiction based on the physician's judgment
- Subjects with TSH >6 mIU/L
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: anti-CD3 monoclonal antibody
Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days.
Up to 9 subjects will be treated at each dosage level
|
Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days.
One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
|
PLACEBO_COMPARATOR: Sodium chloride
Up to 9 subjects will receive placebo.
Subjects will receive the drug in a similar manner as as the treatment group
|
Sodium chloride will be administered orally every day for 30 days.
Up to 9 subjects will be treated at each dosage level.
One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
This clinical study is designed to evaluate as Primary Objective the safety of oral administration of the study drug anti-CD3 MAb to non responder genotype I subjects with the chronic Hepatitis C.
Time Frame: 60
|
The safety and tolerability of oral administration of the study drug cocktail will be evaluated at Days 7, 14, 21 and 30 by physical examinations and thorough medical history and laboratory evaluations as described below and by the subject through his/her diary entries.
In addition, subjects will be assessed for safety at Day 60
|
60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in the concentration of HCV
Time Frame: 30 days
|
30 days
|
30 days
|
Liver function test
Time Frame: 30 days
|
Changes in ALT will be used to evaluate effect on liver
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Waldemar Halota, Prof, Katedra i Klinika Chorób Zakaźnych i Hepatologii Wojewódzki Szpital Obserwacyjno - Zakaźny im. Tadeusza Browicza
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (ANTICIPATED)
May 1, 2013
Study Completion (ANTICIPATED)
October 1, 2013
Study Registration Dates
First Submitted
October 23, 2011
First Submitted That Met QC Criteria
October 23, 2011
First Posted (ESTIMATE)
October 25, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
October 25, 2011
Last Update Submitted That Met QC Criteria
October 23, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis, Chronic
- Hepatitis C, Chronic
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Antibodies, Monoclonal
Other Study ID Numbers
- ISM-10-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hospices Civils de LyonCompleted
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States, Puerto Rico
Clinical Trials on anti-CD3 monoclonal antibody
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Acute Leukemia | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Systemic Mastocytosis | Recurrent Hematologic Malignancy | Hairy Cell Leukemia | Chronic... and other conditions
-
Tiziana Life Sciences LTDWithdrawn
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingB Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | Adult Acute Lymphoblastic Leukemia in Complete RemissionUnited States
-
GlaxoSmithKlineJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 1Italy
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Terminated
-
Brian JonasNational Cancer Institute (NCI); Pharmacyclics LLC.RecruitingPhiladelphia Chromosome Positive | Adult B Acute Lymphoblastic LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingPhiladelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD19 PositiveUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeUnited States
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.TerminatedHER2 Expressing Solid TumoursUnited States, Germany
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States